Galapagos Halts CAR-T Cell Therapy Trial Due to Parkinsonism Case

Trial Pause: Galapagos has temporarily paused patient enrollment in the Phase 1/2 PAPILIO-1 study of GLPG5301, a BCMA-directed CAR-T cell therapy, due to a case of Parkinsonism observed in a patient.
Regulatory Actions: The company has submitted a protocol amendment to the European Medicines Agency (EMA) following the adverse event.
Future Plans: Galapagos anticipates resuming recruitment in the coming months after addressing the safety concerns.
Strategic Collaborations: The company has strengthened its U.S. expansion strategy through a collaboration with Blood Centers of America and has also signed a clinical collaboration agreement with Adaptimmune to advance next-generation TCR T-cell therapy.
Pipeline Progress: Galapagos continues to progress its proprietary R&D pipeline, which includes over 20 clinical and preclinical small molecule and cell therapy programs in oncology and immunology.